News and Announcements
SUDA Presents Data On Novel Penetration-Enhancing Technology
- Published November 17, 2016 3:23PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
17th November 2016
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announced that Mr. Stephen Carter, Managing Director and CEO, presented data on the Company’s novel penetration-enhancing technology at the Annual Symposium of Drug Delivery Systems, being held on 16-19 November 2016 in Nanjing, China.
This scientific conference brings together scientists, academia, healthcare providers, policy makers and investors to provide insights into advances in drug delivery technologies. Mr. Carter chaired a session on “Tackling the Barriers in Different Routes of Drug Delivery.”
SUDA recently filed a provisional patent application with IP Australia for its novel mucosal penetration drug delivery technology. Mr. Carter presented data suggesting that the Company’s new technology, based on unique combinations of hydrotropes, can significantly enhance the permeation of active drugs through the oro-mucosal membrane into the blood system.
If you would like to download the full announcement, please click on the link below.